OR WAIT 15 SECS
DuPont Nutrition and Biosciences has entered into a research collaboration in microbiome science with the Center for Advanced Biotechnology and Medicine at Rutgers University.
DuPont Nutrition and Biosciences (DuPont) has announced, in a July 24, 2020 press release, that it has entered into a research collaboration in microbiome science with the Center for Advanced Biotechnology and Medicine (CABM) at Rutgers University in New Jersey.
The partnership is set to last for two years and will focus on improving the benefit/risk ratio of chemotherapy by decreasing gut inflammation caused by the treatment to potentially improve response rates through modulation of the microbiome. As reported in the press release, according to recent studies, the microbiome plays an important role in gut inflammation and when oncology drugs are taken orally there is a chance of inducing enterocolitis.
“We are privileged to be working with Dr. Martin J. Blaser, Dr. Fang Liu, and their team at Rutgers on a project targeted at improving patient care for those undergoing chemotherapy, and to combine world-class science from Dr. Blaser and his team with our broad portfolio of microbes to further advance the understanding of the intake of beneficial microbes on human health,” said Sébastien Guéry, PhD, human microbiome venture leader, DuPont Nutrition & Biosciences, in the press release.
“We are delighted to further develop our relationship with DuPont for the benefit of human health,” added Martin J. Blaser, director of the CABM at Rutgers University, in the press release. “The interaction of the microbiome with cancer is an important frontier, with important leads already. Our project is aimed to discover new ways to improve cancer therapies.”